Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Biology of adeno-associated viral vectors in the central nervous system

Giridhar Murlidharan, Richard J. Samulski, Aravind Asokan

Frontiers in Molecular Neuroscience · 2014 · Review

doi:10.3389/fnmol.2014.00076

Abstract

Gene therapy is a promising approach for treating a spectrum of neurological and neurodegenerative disorders by delivering corrective genes to the central nervous system (CNS). In particular, adeno-associated viruses (AAVs) have emerged as promising tools for clinical gene transfer in a broad range of genetic disorders with neurological manifestations. In the current review, we have attempted to bridge our understanding of the biology of different AAV strains with their transduction profiles, cellular tropisms, and transport mechanisms within the CNS. Continued efforts to dissect AAV-host interactions within the brain are likely to aid in the development of improved vectors for CNS-directed gene transfer applications in the clinic.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Numerous congenital disorders exhibit distinct manifestations in the central nervous system (CNS). Loss of functionality in affected cell types within the brain can often be attributed to defects in single genes. For instance, a range of neurological disorders arise from the inability of cells in the CNS to break down metabolic end products [e.g., lysosomal storage disorders (LSDs)]. One such example of LSDs with fatal manifestations includes globoid-cell leukodystrophy (GLD) or Krabbe disease in which mutations in galactosylceramidase leads to accumulation of the toxin “psychosine” in the CNS. This disease shows early onset of symptoms like demyelination, astrocyte gliosis etc., and progresses to the death of patients within 2 years of age. Other examples of LSDs include Fabry disease, Gaucher disease, GM1/GM2 gangliosidosis, mucopolysaccharidoses disorders, Pompe disease, and neuronal ceroid lipofuscinosis amongst others.

Another broad category is neurodegenerative disorders, where functionally distinct neuronal subpopulations are lost due to genetic predispositions or environmental toxins. Commonly known examples of this category include dopaminergic (DA) neuronal loss in Parkinson’s disease and GABAergic neuronal loss in Huntington’s disease. A common feature for most of these diseases is severe impairment of combinations of cognitive, motor and sensory functions, leading to loss of quality of life and ultimately death of the patients. Gene therapy holds promise for treating these severely debilitating disorders by delivering healthy cargo of genetic information to specific cell types in the CNS. In particular, adeno-associated viruses (AAVs) have emerged as promising tools for clinical gene transfer in a broad range of genetic disorders with neurological manifestations. In this review, we have attempted to bridge our understanding of the capsid biology of different AAVs with their properties such as transduction efficiencies, cellular tropism and transport within the CNS.

RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS

Adeno-associated viruses are non-enveloped, helper-dependent parvoviruses with an icosahedral capsid architecture ∼25 nm in diameter. AAVs package ∼4.7 kb genome flanked by ∼145 bp inverted terminal repeats (ITRs) on the 5′ and 3′ ends. The wildtype AAV (wtAAV) genome is a linear single stranded DNA consisting of two open reading frames (ORFs). AAV ORFs encode four replication proteins (Rep) and three capsid proteins (Cap/VP) and an assembly activating protein (AAP; ). In addition, wtAAV requires co-infection by adenoviruses or herpes simplex viruses (HSVs) for successful replication and production of viable AAV particles. Three advancements have been instrumental in enabling the use of AAV as a recombinant vector for gene transfer applications: (a) the ability to pseudotype AAV vectors by employing AAV capsids of natural or synthetic origin; (b) cloning and characterization of adenoviral helper genes that are minimally required for generation of infectious AAV particles; and (c) understanding that ITRs are the only cis-acting molecular signature for successful packaging of a transgene within an AAV capsid. These streamlined components are now used to manufacture recombinant AAV (rAAV) vectors packaging a broad spectrum of promoter elements and transgene cassettes for different gene transfer applications. It is noteworthy that due to the aforementioned discoveries, we are now able to manufacture AAV vectors with minimal contamination of the wildtype virions.

Different AAV serotypes exhibit a range of properties pertaining to antigenicity, in vivo tropism and receptor interactions based on their capsid structures. Capsids of different AAV strains bind a spectrum of cell surface glycan receptors and utilize co-receptors for infection. These differences in capsid-receptor interactions play a major role in determining the regional and cellular transduction efficiencies of AAV strains across different mammalian organs. Continued progress in understanding the biology of AAV infection over the past two decades has provided the scientific and clinical community with an arsenal of AAV strains that offer desirable features for CNS gene transfer. In addition to natural isolates, several laboratory-derived AAV strains have been engineered or evolved for specific CNS gene transfer applications. These efforts have yielded novel AAV vectors for targeting (a) glioblastoma cells; (b) rat, mouse and human neural stem cells; and (c) specific regions (piriform cortex and ventral hippocampus) of blood–brain barrier (BBB) compromised rats. We discuss the existing inventory of AAV vectors and their characterization within the CNS below.

BIOLOGY OF AAV CELL ENTRY AND IMPLICATIONS FOR CNS GENE TRANSFER

Successful transduction by AAV vectors is contingent on many key steps like cell surface receptor binding, endocytic uptake, endosomal escape, subsequent nuclear entry, capsid uncoating, genome release, second strand synthesis, and subsequent transcription. Surface exposed regions on the AAV capsids dictate the interactions with the host cell surface. Cell surface glycans have been identified as the preferred primary receptors for many natural AAVs. Accordingly, differences in glycan architecture have been attributed to variations in the efficiency of gene transfer by AAV capsids in different organs. AAV serotypes 1, 5, and 6 bind N-linked sialic acid (SA), whereas AAV4 is the only natural AAV isolate that binds O-linked SA moieties on mammalian cell surfaces. AAV2, three and six bind heparan sulfate (HS) proteoglycans, whereas AAV9 requires N-terminal galactose residues to perform successful gene transfer. Direct injection of HS binding AAV2 in the CNS leads to a largely neuronal transduction profile, whereas SA binding vectors like AAV1 and AAV5 perform efficient neuronal and some glial transduction. The preferential neuronal tropism of AAV2 was later identified to correlate with the comparatively larger availability of heparan sulfate proteoglycans (HSPGs) on the surface of neurons than glia. Interestingly, in addition to enabling the neurotropic bias of AAV2, HS binding has also been associated with restriction of the CNS volume that is effectively targeted by AAV vectors.

It is now known that the lysine residue at position 531 on AAV6 capsid plays an indispensable role in HS binding. By creating HS binding and non-binding variants of AAV1 (AAV1E531K) and AAV6 (AAV6K531E) respectively, demonstrated antagonistic effect of HS binding on CNS transduction of intracranially injected AAVs. Supporting these point mutation studies, co-injection of safe doses of soluble heparin also led to substantial increase in CNS transduction by AAV2. On the other hand, N-terminal galactose binding AAV9 is one of the most efficient vectors for CNS gene transfer. AAV9 has been shown to perform extensive neuronal and glial transduction from different routes of injection in small and large animal models. In addition to important features on the capsid surfaces, efficiency of AAV vector mediated gene transfer can be affected by several post-entry, trafficking and genome-related events within the CNS. Studies pertaining to some of these aspects of AAV biology have been performed within the context of the CNS and discussed later. First we discuss how different AAV strains are influenced by the route of CNS administration below.

DIRECT AAV ADMINISTRATION INTO THE CNS

Direct injections of AAV into the CNS have been used to achieve high levels of transgene expression across different animal models. This strategy of AAV vector administration can be broadly classified into intra-cerebrospinal fluid (CSF) administration and intra-parenchymal administration. The CSF plays a multi-functional role by providing nutrients; molecular and physical cues for important processes like stem cell migration; and removal of interstitial solutes from the brain parenchyma. The CSF is housed within the subarachnoid space, cerebral ventricles, cisterna magna and openings under the cerebellum (foramena), and is in close contact with the spinal cord and brain tissue in the rostrocaudal axis. Understandably, efficient delivery of reporter/therapeutic transgenes to large areas of the CNS has been achieved using AAV injections into cerebral ventricles, cisterna magna, or intravertebral lumbar puncture. Serotypes such as AAV9 and rh.10 exhibit inherently superior ability to spread within the brain parenchyma. These vectors have been used to achieve widespread and long term expression of corrective transgenes from intra-CSF injections toward disease models of spinal muscular atrophy and Krabbe disease. On the other hand, some AAV vectors exhibit highly cell-specific transduction profiles from intra-CSF injections. For instance, intracerebroventricular (ICV) administration of AAV4 leads to selective targeting of astrocytes in the k zone surrounding the cerebral ventricles. The ependyma consists of adult neural stem cells that have the ability to perform lifelong migration, differentiation and repopulation of functionally defined regions in the brain. Indeed, targeted delivery of neurogenic cargo, e.g., noggin and brain derived neurotrophic factor (BDNF) packaged in AAV4 has shown long-term rescue of mouse models of severely debilitating CNS disorders like Huntington’s disease. In addition to these in vivo studies, biophysical analysis of the AAV4 capsid has revealed distinct structural features and low capsid homology among other natural AAV isolates.

Due to the advantages offered by the CSF connectivity of the brain and the spinal cord, AAV vector administration has also been extensively characterized through intrathecal injections (ITs). Traditionally, these injections have been performed by exposing the subarachnoid space at the suboccipital cisterna magna region or the intravertebral space at lumbar region. In general, applications requiring enhanced transduction at the motor, sensory and nociceptive neuronal subpopulations [e.g., within dorsal root ganglia (DRG)] utilize lumbar punctures. AAV serotypes 1, 5, 8, and 9 have shown extensive transduction in the spinal cord and DRG neurons from IT injections at the intravertebral lumbar region. In an independent study, compared IT injections of AAV vectors 1, 6, 8, and 9 for transduction of motor neurons in the spinal cord and brain stem, and reported superior transduction properties of AAV6 and 9. From studies conducted in large animals like pigs and non-human primates (NHPs), a single IT injection of AAV9 has emerged as the candidate procedure for clinical correction of motor neuron disorders affecting the different regions of the spinal cord. As with all these studies, it remains to be seen how vectors pseudotyped with these different capsids respond in a human setting and more importantly, in manifestations of human brain disease.

Direct parenchymal injections of AAV vectors in rodents and NHPs have been traditionally used to achieve transduction within, focused, spatio-functionally distinct regions of the brain. AAV2 shows minimal ability to spread from the parenchymal site of injection and performs preferential gene transfer in the neurons. Unlike other capsid-receptor interactions, the high affinity for HSPGs has been shown to be detrimental to the spread of AAV2 in the brain parenchyma. As discussed earlier, another vector that lacks the ability to spread from the site of intracerebral injection is the NHP isolate AAV4. In another study performed in adult rats, demonstrated that N-linked SA binding AAV1 and AAV5 are superior to AAV2 in terms of spread of transduction from a single parenchymal microinjection into the hippocampus, substantia nigra, globus pallidus, striatum, and spinal cord. Widespread transgene expression was also achieved by parenchymal injections of AAV7, 8 and 9 in rodents. On a cellular level, these vectors preferentially transduced neurons in the adult rodents from clinically relevant stereotaxic injections into the hippocampus, thalamus, cortex and striatum. Interestingly, in addition to capsid serotype, other parameters like age of the animal also seem to affect cellular tropism of AAV vectors from direct brain injections. Using ICV injections of AAVs 1, 8, and 9, demonstrated, that injections performed on postnatal day 0 (P0) leads to preferential neuronal tropism. On the other hand the same vectors showed neuronal and astrocytic transduction profiles from injections performed on P1 or later. Against this backdrop of AAV isolates and serotypes that have been extensively characterized for their receptor interactions, novel AAV serotypes isolated from human beings – AAVhu32, 37, 11, 48R3; and NHPs – AAVrh.8 and 10 have been evaluated in neonatal and adult rodents. Preliminary studies have confirmed the ability of these vectors to perform transduction comparable to AAV9 in rodents, expanding the AAV vector toolkit for CNS gene transfer. For instance, a recent study conducted head to head comparison of AAV 2, 5, 8, and rh.10 for therapeutic delivery of functional “CLN2” transgene in a late infantile neuronal ceroid lipofuscinosis (LINCL) mouse model. Among different serotypes, AAVrh.10 demonstrated comparatively larger spread of transgene expression and restoration of functional levels of the enzyme tripeptidyl-peptidase I, originally lost as a result of mutations in the CLN2 gene. Improvement in motor activities like gait, balance and grip; and amelioration of seizures led to enhanced survival of the treated mice from a single direct brain parenchymal injection. More recent studies evaluating AAVrh.10 administered through different routes in primates have been reviewed in detail in the context of AAV transport within the CNS below.

INTRAVENOUS ADMINISTRATION OF AAV VECTORS FOR CNS GENE TRANSFER

Systemic administration of vectors has the potential to achieve ubiquitous gene transfer of the CNS from a single injection. Additionally, the minimally invasive nature of intravenous (IV) injections adds value to clinical administration of AAV vectors via the bloodstream. Two major roadblocks currently impede our ability to utilize this technique for therapeutic gene transfer of the CNS. The first major concern is the broad biodistribution of AAV vector particles into off-target tissues such as the liver, spleen and kidneys during IV administration of AAVs. For instance, IV injections of AAV9 achieves exceptional transduction of neurons and glia in rodents and NHPs, but also leads to enrichment of viral genomes (∼10 fold or more) in the liver and spleen as compared to the brain. Careful optimization and use of safe dosages of AAV vectors can lead to reduced systemic leakage and associated viral clearance due to neutralizing antibodies. Another approach to reduce peripheral organ toxicity is the occlusion of blood flow into organs like liver and spleen during IV injections of AAVs. Clearly, the use of such techniques requires meticulous optimization of complicated surgical procedures during vector administration before being approved for the clinic. However, it should also be noted that several of these techniques are already approved for use with other drugs/treatments in the clinical setting. Another important problem is the inability of the majority of well-characterized AAV vectors to efficiently cross the BBB and transduce cells within the CNS. In order to successfully transduce cells in the CNS, systemically injected virions are thought to undergo receptor mediated transport to cross the brain microvasculature. However, the exact mechanism(s), paracellular or transcellular remain to be determined. Tight junctions in the endothelial cells, astrocytic endfeet and pericytes are known to collectively constitute the BBB. Intra-arterial infusion of mannitol leads to transient opening of the BBB without eliciting any permanent damage. Short-term disruption of these checkpoints by administration of mannitol led to effective CNS transduction by IV injections of AAV2 which is unable to cross the BBB.

A recent study compared CNS transduction from injections of AAVs 1, 2, 5, 6, 7, 9, Rh.10, Rh.39, and Rh.43 into the superficial temporal vein of neonatal mice (P1). Successful, but differential levels of CNS transduction were reported from all tested vectors (except AAVs 2 and 5; ). Additionally, some leading examples of AAV vectors that have been tested in adult rodents and NHPs include AAVs 8, 9, Rh.8, and Rh.10. These results clearly indicate that many AAV serotypes have been associated with a range of cellular and regional CNS gene transfer properties from systemic injections. In this regard, a better understanding of capsid structural motifs that allow certain AAV strains to traverse the BBB is critical. For instance, using directed evolution, have engineered two AAV capsids capable of crossing seizure compromised-BBB in rats. The original library of AAVs from which the candidate capsid was isolated included AAVs 1–6, 8, and 9. Careful assessment of the parental and evolved capsid sequences might provide further insights into capsid domains possibly involved in CNS transduction after IV administration. Along similar lines, peptide motifs have been identified that impart AAV capsids with the ability to cross the brain microvasculature. IV injection of a peptide modified version of the AAV2 packaging β-glucuronidase was used to achieve significant clearance of lysosomal storage burden, leading to cognitive benefits and prolonged survival in a mucopolysacharidoses VII mouse model. It is noteworthy that IV administration of the corrective transgene packaged in AAV9 capsid was unable to confer therapeutic benefits. It was later identified using fluorescein labeled Sambucus nigra lectin that enhanced SA depositions in the MPS VII affected mouse CNS might be detrimental for AAV9-mediated CNS transduction. Such results demonstrate that the biology of different AAV strains can be affected by specific disease phenotypes that alter the molecular composition(s) of different cell types within the brain.

AAV TRANSPORT WITHIN THE CNS

Subsequent to vector administration and engagement of cell surface attachment factors such as glycans, AAV vectors appear to undergo interstitial as well as intracellular transport within the CNS. For instance, recent studies in the primate brain have demonstrated that AAVrh.10 displays distinct transduction patterns following different routes of administration. Of the five routes tested, delivery to parenchyma resulted in more efficient gene transfer than intraventricular or intraarticular routes of administration. Another study in marmosets demonstrated that IV administration of AAVrh.10 is capable of efficient CNS transduction. These results highlight the potential diversity in AAV vector transport mechanisms not only in the context of brain physiology, but also possibly due to vector serotype, receptor usage and animal models. Although not completely understood, two mechanisms, namely paravascular CSF transport and axonal transport appear to play a role in controlling the spread of AAV vectors within the CNS. It has been established that the paravascular transport of CSF plays a major role in the spread of interstitial fluid (ISF) within the CNS. One of the earliest studies demonstrated that proteins accumulate along highly vascularized regions of forebrain and brainstem within minutes of ICV injections. Further, medically induced blood pressure fluctuations have been directly shown to control the spread of nanoparticles including AAVs in the brain. The brain is distinct from other organs in that it lacks lymphatic circulation. To understand compensatory mechanisms, performed CNS-injections of differently sized (between 750 da and 2000 kda) molecular tracers. Using compelling visual evidence provided by 2-photon microscopy, the authors concluded that paravascular movement of CSF clears solutes from the CNS. Specifically, the para-arterial influx and the paravenous efflux of subarachnoid CSF drain accumulations of metabolic end products and other solutes within the brain parenchyma. These results suggest that mechanisms like the CSF transport can possibly play a role in determining the extent of spread of viruses within the CNS. Clearly, understanding the structure-function correlates of AAV capsids and host factors that might dictate their ability to spread in the brain against the backdrop of CNS physiology will be valuable.

Another known pathway that viruses utilize to spread within the CNS is axonal transport post-entry into host neurons. Viruses can travel long distances by getting transported across synaptic connections in various sectors of mammalian central and peripheral nervous system. Over the years, HSV and pseudorabies virus (PRV) have been used to visualize axonal transport and the resulting patterns of viral infections in the CNS milieu. Although accurate neuronal tracing has been achieved using these viruses, a major disadvantage is the loss of gene expression and neuronal death observed in the labeled cells between 5 days and 2 weeks post-infection. In case of AAVs, both unidirectional and bidirectional axonal transport has been observed depending on the viral strain. During retrograde transport, intact virions are taken up at the axonal projections and are transported to the neuronal cell body (soma), where the virus enters the nucleus to perform transduction. Conversely, a successful anterograde transport requires virions to enter the neuronal soma and travel along the length of the axon to finally get released at the projections. The released virions are then free to transduce new cellular subpopulations in the region.

Understandably, directional axonal transport of AAV can be utilized to achieve safe and targeted gene delivery in spatially and functionally distinct neuronal subpopulations. For instance, AAV2 specifically undergoes anterograde transport. On the other hand, AAV6 exhibits exclusive retrograde transport in both rat and primate brain. In addition, AAV9 has been shown to efficiently travel in both anterograde and retrograde directions. Specifically, visualized dye-conjugated AAV9 vectors during their anterograde and retrograde movements within cultured rat cortical neurons. These studies showed that axonal transport of AAV9 occurs in Rab7 positive late endosomal/lysosomal compartments. Further, cytoplasmic dynein and kinesin-2 were identified as being critical for successful retrograde and anterograde transport, respectively.

SAFETY ASPECTS

Recombinant AAV vector genomes display inefficient integration into the host chromosome and predominantly persist in episomal form. This reduces the risk of insertional mutagenesis, often associated with other viral vectors like retroviruses. The vector genomes subsequently require the host cellular machinery to carry out second strand synthesis, transcription and translation. Safety aspects pertaining to persistence of AAV vector genomes in the CNS are forthcoming and have been reviewed in general elsewhere. Another important safety consideration is the observation that rAAV mediated overexpression of non-self transgenes can elicit immune responses due to antigen presentation of the expressed transgene product. For instance, direct primate brain infusion of AAV1 packaging a humanized Renilla GFP transgene triggered an immune response against the translated reporter product. Similarly, a cell mediated immune response and neuronal loss was observed in rats injected with AAV9 vectors packaging the GFP reporter transgene or a human L-amino acid decarboxylase transgene. More recently, certain AAV serotypes have been shown to undergo systemic leakage resulting in off-target biodistribution in organs like liver and spleen. These preliminary observations in animal models highlight the need to better understand the parameters that determine potential toxicity/biodistribution profiles and immune response in AAV-mediated CNS gene transfer. It is also important to acknowledge that aspects related to manufacturing, downstream processing and purity of AAV vector preparations are critical toward ensuring the safety of AAV vectors. A comprehensive comparison of different viral gene transfer vectors for parameters such as packaging capacity, host chromosomal integration and other biosafety aspects can be found elsewhere.

SUMMARY

As of early 2014, 5.3% of world-wide clinical trials involving gene therapy have utilized AAV vectors (109 ongoing trials; Journal of Gene Medicine). Only a few of these trials are aimed at treating diseases with CNS manifestations. In the current review, we have attempted to provide an overview of various parameters that might play a role in determining the success of AAV mediated therapeutic gene transfer to the CNS. Interactions of AAV vectors with different primary receptors, directional transport and cellular tropisms following different routes of administration are summarized in Table 1. Although we were unable to cover every contribution to the field of CNS gene therapy, we hope that the information provided in this review not only highlights potential gaps in our understanding of AAV-host interactions within the CNS, but will assist with continued vector development for CNS-directed gene transfer applications in the clinic.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 114

  1. 1.

    Abbott N. J. (2004 ). Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 45 545–552

    Not in our library10.1016/j.neuint.2003.11.006

  2. 2.

    Agbandje-McKenna M. Kleinschmidt J. (2011 ). AAV capsid structure and cell interactions. Methods Mol. Biol. 807 47–92

    Not in our library10.1007/978-1-61779-370-7_3

  3. 3.

    Ahmed S. S. Li H. Cao C. Sikoglu E. M. Denninger A. R. Su Q. (2013 ). A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS gene therapy in canavan mice. Mol. Ther. 21 2136–2147

    Not in our library10.1038/mt.2013.138

  4. 4.

    Alvarez-Buylla A. Lim D. A. (2004 ). For the long run: maintaining germinal niches in the adult brain. Neuron 41 683–686

    Not in our library10.1016/s0896-6273(04)00111-4

  5. 5.

    Arnett A. L. Beutler L. R. Quintana A. Allen J. Finn E. Palmiter R. D. (2013 ). Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Ther. 20 497–503

    Not in our library10.1038/gt.2012.60

  6. 6.

    Asokan A. Schaffer D. V. Jude Samulski R. (2012 ). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20 699–708

    Not in our library10.1038/mt.2011.287

  7. 7.

    Bartlett J. S. Samulski R. J. McCown T. J. (1998 ). Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9 1181–1186

    Not in our library10.1089/hum.1998.9.8-1181

  8. 8.

    Beier K. T. Saunders A. Oldenburg I. A. Miyamichi K. Akhtar N. Luo L. (2011 ). Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors. Proc. Natl. Acad. Sci. U.S.A. 108 15414–15419

    Not in our library10.1073/pnas.1110854108

  9. 9.

    Bell C. L. Vandenberghe L. H. Bell P. Limberis M. P. Gao G. P. Van Vliet K. (2011 ). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121 2427–2435

    Not in our library10.1172/jci57367

  10. 10.

    Benkhelifa-Ziyyat S. Besse A. Roda M. Duque S. Astord S. Carcenac R. (2013 ). Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol. Ther. 21 282–290

    Not in our library10.1038/mt.2012.261

  11. 11.

    Benraiss A. Bruel-Jungerman E. Lu G. Economides A. N. Davidson B. Goldman S. A. (2012 ). Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF. Gene Ther. 19 483–493

    Not in our library10.1038/gt.2011.114

  12. 12.

    Bevan A. K. Duque S. Foust K. D. Morales P. R. Braun L. Schmelzer L. (2011 ). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19 1971–1980

    Not in our library10.1038/mt.2011.157

  13. 13.

    Bockstael O. Melas C. Pythoud C. Levivier M. McCarty D. Samulski R. J. (2012 ). Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors. Hum. Gene Ther. 23 742–753

    Not in our library10.1089/hum.2011.216

  14. 14.

    Bokhoven M. Stephen S. L. Knight S. Gevers E. F. Robinson I. C. Takeuchi Y. (2009 ). Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83 283–294

    Not in our library10.1128/jvi.01865-08

  15. 15.

    Boustany R. M. (2013 ). Lysosomal storage diseases – the horizon expands. Nat. Rev. Neurol. 9 583–598

    Not in our library10.1038/nrneurol.2013.163

  16. 16.

    Bowles D. E. Rabinowitz J. E. Samulski R. J. (2006 ). “The genus dependovirus,” in Parvoviruses eds Kerr J. R. Cotmore S. F. Bloom M. E. Linden R. M. Parrish C. R. (New York: Edward Arnold Ltd.) 15–24

    Not in our library

  17. 17.

    Broekman M. L. Comer L. A. Hyman B. T. Sena-Esteves M. (2006 ). Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138 501–510

    Not in our library10.1016/j.neuroscience.2005.11.057

  18. 18.

    Burger C. Gorbatyuk O. S. Velardo M. J. Peden C. S. Williams P. Zolotukhin S. (2004 ). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 302–317

    Not in our library10.1016/j.ymthe.2004.05.024

  19. 19.

    Cabrera-Salazar M. A. Bercury S. D. Ziegler R. J. Marshall J. Hodges B. L. Chuang W. L. (2010 ). Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic gaucher disease. Exp. Neurol. 225 436–444

    Not in our library10.1016/j.expneurol.2010.07.023

  20. 20.

    Castle M. J. Gershenson Z. T. Giles A. R. Holzbaur E. L. Wolfe J. H. (2014a ). Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. Hum. Gene Ther. 25 705–720

    Not in our library10.1089/hum.2013.189

  21. 21.

    Castle M. J. Perlson E. Holzbaur E. L. Wolfe J. H. (2014b ). Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment. Mol. Ther. 22 554–566

    Not in our library10.1038/mt.2013.237

  22. 22.

    Cearley C. N. Vandenberghe L. H. Parente M. K. Carnish E. R. Wilson J. M. Wolfe J. H. (2008 ). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16 1710–1718

    Not in our library10.1038/mt.2008.166

  23. 23.

    Cearley C. N. Wolfe J. H. (2006 ). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13 528–537

    Not in our library10.1016/j.ymthe.2005.11.015

  24. 24.

    Cearley C. N. Wolfe J. H. (2007 ). A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27 9928–9940

    Not in our library10.1523/jneurosci.2185-07.2007

  25. 25.
    Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice Brain · 2013
    No notice
  26. 26.

    Chamberlin N. L. Du B. de Lacalle S. Saper C. B. (1998 ). Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res. 793 169–175

    Not in our library10.1016/s0006-8993(98)00169-3

  27. 27.

    Chen Y. H. Claflin K. Geoghegan J. C. Davidson B. L. (2012 ). Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol. Ther. 20 1393–1399

    Not in our library10.1038/mt.2012.100

  28. 28.

    Ciesielska A. Hadaczek P. Mittermeyer G. Zhou S. Wright J. F. Bankiewicz K. S. (2013 ). Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol. Ther. 21 158–166

    Not in our library10.1038/mt.2012.167

  29. 29.

    Ciesielska A. Mittermeyer G. Hadaczek P. Kells A. P. Forsayeth J. Bankiewicz K. S. (2011 ). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19 922–927

    Not in our library10.1038/mt.2010.248

  30. 30.

    Cserr H. F. Harling-Berg C. J. Knopf P. M. (1992 ). Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 2 269–276

    Not in our library10.1111/j.1750-3639.1992.tb00703.x

  31. 31.
    Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system · 2000
    Not checked
  32. 32.

    Dayton R. D. Wang D. B. Klein R. L. (2012 ). The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin. Biol. Ther. 12 757–766

    Not in our library10.1517/14712598.2012.681463

  33. 33.

    Dismuke D. J. Tenenbaum L. Samulski R. J. (2013 ). Biosafety of recombinant adeno-associated virus vectors. Curr. Gene Ther. 13 434–452

    Not in our library10.2174/15665232113136660007

  34. 34.

    Duan D. Sharma P. Yang J. Yue Y. Dudus L. Zhang Y. (1998 ). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72 8568–8577

    Not in our library10.1128/jvi.72.11.8568-8577.1998

  35. 35.

    Federici T. Taub J. S. Baum G. R. Gray S. J. Grieger J. C. Matthews K. A. (2012 ). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19 852–859

    Not in our library10.1038/gt.2011.130

  36. 36.

    Foust K. D. Nurre E. Montgomery C. L. Hernandez A. Chan C. M. Kaspar B. K. (2009 ). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27 59–65

    Not in our library10.1038/nbt.1515

  37. 37.

    Fu H. Kang L. Jennings J. S. Moy S. S. Perez A. Dirosario J. (2007 ). Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther. 14 1065–1077

    Not in our library10.1038/sj.gt.3302961

  38. 38.

    Fu H. Muenzer J. Samulski R. J. Breese G. Sifford J. Zeng X. (2003 ). Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8 911–917

    Not in our library10.1016/j.ymthe.2003.08.021

  39. 39.

    Gao G. P. Alvira M. R. Wang L. Calcedo R. Johnston J. Wilson J. M. (2002 ). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 11854–11859

    Not in our library10.1073/pnas.182412299

  40. 40.

    Gao G. Vandenberghe L. H. Alvira M. R. Lu Y. Calcedo R. Zhou X. (2004 ). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 6381–6388

    Not in our library10.1128/jvi.78.12.6381-6388.2004

  41. 41.

    Glascock J. J. Osman E. Y. Wetz M. J. Krogman M. M. Shababi M. Lorson C. L. (2012 ). Decreasing disease severity in symptomatic, smn(–/–);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery. Hum. Gene Ther. 23 330–335

    Not in our library10.1089/hum.2011.166

  42. 42.

    Govindasamy L. Padron E. McKenna R. Muzyczka N. Kaludov N. Chiorini J. A. (2006 ). Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80 11556–11570

    Not in our library10.1128/jvi.01536-06

  43. 43.

    Granstedt A. E. Brunton B. W. Enquist L. W. (2013 ). Imaging the transport dynamics of single alphaherpesvirus particles in intact peripheral nervous system explants from infected mice. MBio 4:e00358–e00313

    Not in our library10.1128/mbio.00358-13

  44. 44.

    Gray S. J. (2013 ). Gene therapy and neurodevelopmental disorders. Neuropharmacology 68 136–142

    Not in our library10.1016/j.neuropharm.2012.06.024

  45. 45.

    Gray S. J. Blake B. L. Criswell H. E. Nicolson S. C. Samulski R. J. McCown T. J. (2010 ). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18 570–578

    Not in our library10.1038/mt.2009.292

  46. 46.

    Gray S. J. Matagne V. Bachaboina L. Yadav S. Ojeda S. R. Samulski R. J. (2011 ). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19 1058–1069

    Not in our library10.1038/mt.2011.72

  47. 47.

    Gray S. J. Nagabhushan Kalburgi S. McCown T. J. Jude Samulski R. (2013 ). Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20 450–459

    Not in our library10.1038/gt.2012.101

  48. 48.

    Grieger J. C. Choi V. W. Samulski R. J. (2006 ). Production and characterization of adeno-associated viral vectors. Nat. Protoc. 1 1412–1428

    Not in our library10.1038/nprot.2006.207

  49. 49.

    Hadaczek P. Forsayeth J. Mirek H. Munson K. Bringas J. Pivirotto P. (2009 ). Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum. Gene Ther. 20 225–237

    Not in our library10.1089/hum.2008.151

  50. 50.

    Hadaczek P. Yamashita Y. Mirek H. Tamas L. Bohn M. C. Noble C. (2006 ). The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14 69–78

    Not in our library10.1016/j.ymthe.2006.02.018

  51. 51.

    Handa A. Muramatsu S. Qiu J. Mizukami H. Brown K. E. (2000 ). Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 81(Pt 8) 2077–2084

    Not in our library10.1099/0022-1317-81-8-2077

  52. 52.

    Hirai T. Enomoto M. Machida A. Yamamoto M. Kuwahara H. Tajiri M. (2012 ). Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum. Gene Ther. Methods 23 119–127

    Not in our library10.1089/hgtb.2012.035

  53. 53.

    Hollis E. R. II Kadoya K. Hirsch M. Samulski R. J. Tuszynski M. H. (2008 ). Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol. Ther. 16 296–301

    Not in our library10.1038/sj.mt.6300367

  54. 54.

    Hsueh Y. P. Sheng M. (1999 ). Regulated expression and subcellular localization of syndecan heparan sulfate proteoglycans and the syndecan-binding protein CASK/LIN-2 during rat brain development. J. Neurosci. 19 7415–7425.

    Not in our library10.1523/jneurosci.19-17-07415.1999

  55. 55.

    Hsueh Y. P. Yang F. C. Kharazia V. Naisbitt S. Cohen A. R. Weinberg R. J. (1998 ). Direct interaction of CASK/LIN-2 and syndecan heparan sulfate proteoglycan and their overlapping distribution in neuronal synapses. J. Cell Biol. 142 139–151

    Not in our library10.1083/jcb.142.1.139

  56. 56.

    Huang L. Y. Halder S. Agbandje-McKenna M. (2014 ). Parvovirus glycan interactions. Curr. Opin. Virol. 7C, 108–118

    Not in our library10.1016/j.coviro.2014.05.007

  57. 57.

    Iliff J. J Wang M. Liao Y. Plogg B. A. Peng W. Gundersen G. A. (2012 ). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 4:147ra111

    Not in our library10.1126/scitranslmed.3003748

  58. 58.

    Irwin D. J. Lee V. M. Trojanowski J. Q. (2013 ). Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14 626–636

    Not in our library10.1038/nrn3549

  59. 59.

    Iwata N. Sekiguchi M. Hattori Y. Takahashi A. Asai M. Ji B. (2013 ). Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci. Rep. 3:1472

    Not in our library10.1038/srep01472

  60. 60.

    Jacques S. J. Ahmed Z. Forbes A. Douglas M. R. Vigenswara V. Berry M. (2012 ). AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection. Mol. Cell. Neurosci. 49 464–474

    Not in our library10.1016/j.mcn.2012.03.002

  61. 61.

    Jang J. H. Koerber J. T. Kim J. S. Asuri P. Vazin T. Bartel M. (2011 ). An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19 667–675

    Not in our library10.1038/mt.2010.287

  62. 62.

    Kaludov N. Brown K. E. Walters R. W. Zabner J. Chiorini J. A. (2001 ). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75 6884–6893

    Not in our library10.1128/jvi.75.15.6884-6893.2001

  63. 63.

    Kawamoto S. Shi Q. Nitta Y. Miyazaki J. Allen M. D. (2005 ). Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol. Ther. 11 980–985

    Not in our library10.1016/j.ymthe.2005.02.009

  64. 64.

    Kells A. P. Hadaczek P. Yin D. Bringas J. Varenika V. Forsayeth J. (2009 ). Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl. Acad. Sci. U.S.A. 106 2407–2411

    Not in our library10.1073/pnas.0810682106

  65. 65.
    Integration of the subarachnoid space and lymphatics: Is it time to embrace a new concept of cerebrospinal fluid absorption? · 2005
    No notice
  66. 66.

    Lehtinen M. K. Bjornsson C. S. Dymecki S. M. Gilbertson R. J. Holtzman D. M. Monuki E. S. (2013 ). The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. J. Neurosci. 33 17553–17559

    Not in our library10.1523/jneurosci.3258-13.2013

  67. 67.

    Lentz T. B. Gray S. J. Samulski R. J. (2012 ). Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis. 48 179–188

    Not in our library10.1016/j.nbd.2011.09.014

  68. 68.

    Lin D. Fantz C. R. Levy B. Rafi M. A. Vogler C. Wenger D. A. (2005 ). AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol. Ther. 12 422–430

    Not in our library10.1016/j.ymthe.2005.04.019

  69. 69.

    Liu G. Martins I. H. Chiorini J. A. Davidson B. L. (2005a ). Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther. 12 1503–1508

    Not in our library10.1038/sj.gt.3302554

  70. 70.

    Liu G. Martins I. Wemmie J. A. Chiorini J. A. Davidson B. L. (2005b ). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25 9321–9327

    Not in our library10.1523/jneurosci.2936-05.2005

  71. 71.

    Low K. Aebischer P. Schneider B. L. (2013 ). Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. Hum. Gene Ther. 24 613–629

    Not in our library10.1089/hum.2012.174

  72. 72.

    Maguire C. A. Gianni D. Meijer D. H. Shaket L. A. Wakimoto H. Rabkin S. D. (2010 ). Directed evolution of adeno-associated virus for glioma cell transduction. J. Neurooncol. 96 337–347

    Not in our library10.1007/s11060-009-9972-7

  73. 73.

    Mandel R. J. Burger C. (2004 ). Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6 482–490

    Not in our library

  74. 74.

    Masamizu Y. Okada T. Kawasaki K. Ishibashi H. Yuasa S. Takeda S. (2011 ). Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9. Neuroscience 193 249–258

    Not in our library10.1016/j.neuroscience.2011.06.080

  75. 75.

    Mastakov M. Y. Baer K. Kotin R. M. During M. J. (2002 ). Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. Mol. Ther. 5 371–380

    Not in our library10.1006/mthe.2002.0564

  76. 76.

    McCarty D. M. DiRosario J. Gulaid K. Muenzer J. Fu H. (2009 ). Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther. 16 1340–1352

    Not in our library10.1038/gt.2009.85

  77. 77.

    McCarty D. M. Young S. M. Jr. Samulski R. J. (2004 ). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38 819–845

    Not in our library10.1146/annurev.genet.37.110801.143717

  78. 78.

    McCown T. J. Xiao X. Li J. Breese G. R. Samulski R. J. (1996 ). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713 99–107

    Not in our library10.1016/0006-8993(95)01488-8

  79. 79.

    Nash K. Chen W. Muzyczka N. (2008 ). Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. J. Virol. 82 1458–1464

    Not in our library10.1128/jvi.01968-07

  80. 80.

    Nguyen J. B. Sanchez-Pernaute R. Cunningham J. Bankiewicz K. S. (2001 ). Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12 1961–1964

    Not in our library10.1097/00001756-200107030-00037

  81. 81.

    Orr H. T. Zoghbi H. Y. (2007 ). Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30 575–621

    Not in our library10.1146/annurev.neuro.29.051605.113042

  82. 82.

    Osakada F. Mori T. Cetin A. H. Marshel J. H. Virgen B. Callaway E. M. (2011 ). New rabies virus variants for monitoring and manipulating activity and gene expression in defined neural circuits. Neuron 71 617–631

    Not in our library10.1016/j.neuron.2011.07.005

  83. 83.

    Padron E. Bowman V. Kaludov N. Govindasamy L. Levy H. Nick P. (2005 ). Structure of adeno-associated virus type 4. J. Virol. 79 5047–5058

    Not in our library10.1128/jvi.79.8.5047-5058.2005

  84. 84.

    Passini M. A. Wolfe J. H. (2001 ). Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J. Virol. 75 12382–12392

    Not in our library10.1128/jvi.75.24.12382-12392.2001

  85. 85.

    Rabinowitz J. E. Rolling F. Li C. Conrath H. Xiao W. Xiao X. (2002 ). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76 791–801

    Not in our library10.1128/jvi.76.2.791-801.2002

  86. 86.

    Rafi M. A. Rao H. Z. Luzi P. Curtis M. T. Wenger D. A. (2012 ). Extended normal life after AAVrh10-mediated gene therapy in the mouse model of krabbe disease. Mol. Ther. 20 2031–2042

    Not in our library10.1038/mt.2012.153

  87. 87.

    Rennels M. L. Gregory T. F. Blaumanis O. R. Fujimoto K. Grady P. A. (1985 ). Evidence for a “paravascular” fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 326 47–63

    Not in our library10.1016/0006-8993(85)91383-6

  88. 88.

    Rosenberg J. B. Sondhi D. Rubin D. G. Monette S. Chen A. Cram S. (2014 ). Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum. Gene Ther. Clin. Dev. [Epub ahead of print]

    Not in our library10.1089/humc.2013.239

  89. 89.

    Rothermel M. Brunert D. Zabawa C. Diaz-Quesada M. Wachowiak M. (2013 ). Transgene expression in target-defined neuron populations mediated by retrograde infection with adeno-associated viral vectors. J. Neurosci. 33 15195–15206

    Not in our library10.1523/jneurosci.1618-13.2013

  90. 90.

    Salegio E. A. Samaranch L. Kells A. P. Mittermeyer G. San Sebastian W. Zhou S. (2013 ). Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 20 348–352

    Not in our library10.1038/gt.2012.27

  91. 91.

    Samaranch L. Salegio E. A. San Sebastian W. Kells A. P. Bringas J. R. Forsayeth J. (2013 ). Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24 526–532

    Not in our library10.1089/hum.2013.005

  92. 92.

    Samaranch L. Salegio E. A. San Sebastian W. Kells A. P. Foust K. D. Bringas J. R. (2012 ). Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23 382–389

    Not in our library10.1089/hum.2011.200

  93. 93.

    San Sebastian W. Samaranch L. Heller G. Kells A. P. Bringas J. Pivirotto P. (2013 ). Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther. 20 1178–1183

    Not in our library10.1038/gt.2013.48

  94. 94.

    Sawamoto K. Wichterle H. Gonzalez-Perez O. Cholfin J. A. Yamada M. Spassky N. (2006 ). New neurons follow the flow of cerebrospinal fluid in the adult brain. Science 311 629–632

    Not in our library10.1126/science.1119133

  95. 95.

    Shen F. Kuo R. Milon-Camus M. Han Z. Jiang L. Young W. L. (2013 ). Intravenous delivery of adeno-associated viral vector serotype 9 mediates effective gene expression in ischemic stroke lesion and brain angiogenic foci. Stroke 44 252–254

    Not in our library10.1161/strokeaha.112.662965

  96. 96.

    Shen S. Bryant K. D. Brown S. M. Randell S. H. Asokan A. (2011 ). Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286 13532–13540

    Not in our library10.1074/jbc.m110.210922

  97. 97.

    Simonato M. Bennett J. Boulis N. M. Castro M. G. Fink D. J. Goins W. F. (2013 ). Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9 277–291

    Not in our library10.1038/nrneurol.2013.56

  98. 98.

    Snyder B. R. Gray S. J. Quach E. T. Huang J. W. Leung C. H. Samulski R. J. (2011 ). Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 22 1129–1135

    Not in our library10.1089/hum.2011.008

  99. 99.

    Sondhi D. Hackett N. R. Peterson D. A. Stratton J. Baad M. Travis K. M. (2007 ). Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15 481–491

    Not in our library10.1038/sj.mt.6300049

  100. 100.

    Summerford C. Samulski R. J. (1998 ). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 1438–1445

    Not in our library10.1128/jvi.72.2.1438-1445.1998

  101. 101.

    Taylor M. P. Kobiler O. Enquist L. W. (2012 ). Alphaherpesvirus axon-to-cell spread involves limited virion transmission. Proc. Natl. Acad. Sci. U.S.A. 109 17046–17051

    Not in our library10.1073/pnas.1212926109

  102. 102.

    Tenenbaum L. Chtarto A. Lehtonen E. Velu T. Brotchi J. Levivier M. (2004 ). Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene Med. 6(Suppl. 1) S212–S222

    Not in our library10.1002/jgm.506

  103. 103.

    Vandenberghe L. H. Wilson J. M. Gao G. (2009 ). Tailoring the AAV vector capsid for gene therapy. Gene Ther. 16 311–319

    Not in our library10.1038/gt.2008.170

  104. 104.

    Vulchanova L. Schuster D. J. Belur L. R. Riedl M. S. Podetz-Pedersen K. M. Kitto K. F. (2010 ). Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol. Pain 6:31

    Not in our library10.1186/1744-8069-6-31

  105. 105.

    Walters R. W. Yi S. M. Keshavjee S. Brown K. E. Welsh M. J. Chiorini J. A. (2001 ). Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276 20610–20616

    Not in our library10.1074/jbc.m101559200

  106. 106.

    Wenger D. A. Coppola S. Liu S. L. (2002 ). Lysosomal storage disorders: diagnostic dilemmas and prospects for therapy. Genet. Med. 4 412–419

    Not in our library10.1097/00125817-200211000-00003

  107. 107.

    Wickersham I. R. Finke S. Conzelmann K. K. Callaway E. M. (2007 ). Retrograde neuronal tracing with a deletion-mutant rabies virus. Nat. Methods 4 47–49

    Not in our library10.1038/nmeth999

  108. 108.

    Wu Z. Asokan A. Grieger J. C. Govindasamy L. Agbandje-McKenna M. Samulski R. J. (2006a ). Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80 11393–11397

    Not in our library10.1128/jvi.01288-06

  109. 109.

    Wu Z. Miller E. Agbandje-McKenna M. Samulski R. J. (2006b ). Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80 9093–9103

    Not in our library10.1128/jvi.00895-06

  110. 110.

    Xiao X. Li J. Samulski R. J. (1998 ). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72 2224–2232

    Not in our library10.1128/jvi.72.3.2224-2232.1998

  111. 111.

    Xiao X. Xiao W. Li J. Samulski R. J. (1997 ). A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71 941–948

    Not in our library10.1128/jvi.71.2.941-948.1997

  112. 112.

    Yamashita T. Chai H. L. Teramoto S. Tsuji S. Shimazaki K. Muramatsu S. (2013 ). Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol. Med. 5 1710–1719

    Not in our library10.1002/emmm.201302935

  113. 113.

    Yang B. Li S. Wang H. Guo Y. Gessler D. J. Cao C. (2014 ). Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol. Ther. 22 1299–1309

    Not in our library10.1038/mt.2014.68

  114. 114.

    Zhang H. Yang B. Mu X. Ahmed S. S. Su Q. He R. (2011 ). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19 1440–1448

    Not in our library10.1038/mt.2011.98

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.